Sage Therapeutics
SAGE
SAGE was delisted on the 30th of July, 2025.
217 hedge funds and large institutions have $2.14B invested in Sage Therapeutics in 2021 Q4 according to their latest regulatory filings, with 17 funds opening new positions, 78 increasing their positions, 72 reducing their positions, and 32 closing their positions.
64% more call options, than puts
Call options by funds: $53.2M | Put options by funds: $32.4M
22% more capital inflows, than outflows
Capital inflows: $184M | Capital outflows: $151M
1.74% more ownership
Funds ownership: 83.45% → 85.19% (+1.7%)
8% more repeat investments, than reductions
Existing positions increased: 78 | Existing positions reduced: 72
4% less funds holding
Funds holding: 227 → 217 (-10)
33% less funds holding in top 10
Funds holding in top 10: 3 → 2 (-1)
47% less first-time investments, than exits
New positions opened: 17 | Existing positions closed: 32
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EcoR1 Capital
San Francisco,
California
|
+$39.4M |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$17.9M |
| 3 |
JP Morgan Chase
New York
|
+$16.6M |
| 4 |
Wellington Management Group
Boston,
Massachusetts
|
+$14.9M |
| 5 |
First Trust Advisors
Wheaton,
Illinois
|
+$9.31M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
-$17.6M |
| 2 |
Great Point Partners
Greenwich,
Connecticut
|
-$11.9M |
| 3 |
D.E. Shaw & Co
New York
|
-$11M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
-$10.6M |
| 5 |
ACM
Asymmetry Capital Management
San Francisco,
California
|
-$10.2M |
SAGE Hedge Fund Activity: Q4 2021 in Review
217 of the 6,518 institutional investors tracked by Wall St. Rank reported a position in Sage Therapeutics (SAGE) for Q4 2021, worth a combined $2.14B — down 1.8% from $2.17B a quarter earlier.
Sellers outnumbered buyers: 32 funds closed out of SAGE and 17 opened new positions — a net loss of 15 holders — while 72 trimmed existing stakes and 78 added.
The largest buyer was EcoR1 Capital, opening a new position worth an estimated $39.4M. The largest seller was Point72 Asset Management, cutting an estimated $17.6M.
- 217 institutional investors held Sage Therapeutics (SAGE) as of Q4 2021, down from 227 in Q3 2021.
- Funds reported $2.14B of Sage Therapeutics stock for Q4 2021, down 1.8% quarter-over-quarter.
- 17 funds opened new Sage Therapeutics positions in Q4 2021 and 32 closed out, a net change of -15 holders.
- The largest Sage Therapeutics buyer in Q4 2021 was EcoR1 Capital, an estimated $39.4M added.
- The largest Sage Therapeutics seller in Q4 2021 was Point72 Asset Management, an estimated $17.6M sold.
Based on aggregated 13F filings for Q4 2021.